1. Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse May 22, 2002 (Prepared by Linda Thomas)

2. Overview of 1 st 172 days… 172 days… 10 hours… 10 hours… 14 minutes… 14 minutes… (but who’s counting?)

3. William Corrigall, Ph.D. - Chief, TRB, DNBR and Director, Nicotine and Tobacco Addiction Program William Corrigall, Ph.D. - Chief, TRB, DNBR and Director, Nicotine and Tobacco Addiction Program Ron A. Dobbins - CCTN Recent NIDA Staff Appointments Susan E. Martin, Ph.D. – DESPR Dawn Rabunsky – OPRM, CMB Dave Daubert – OPRM, MASB Charlotte Annan – OD/SPO Redonna Chandler, Ph.D. – DESPR Bev Pringle, Ph.D. – DESPR

4. Dr. Ahmed Elkashef - Physician Research of the Year Award from PHS Commissioned Corps Dr. Ahmed Elkashef - Physician Research of the Year Award from PHS Commissioned Corps Diana Haikalis – Letter of Appreciation Recent Staff Awards Debra Battle-Dudley – Letter of Appreciation Daisey Parker – Letter of Appreciation Deborah Wertz – Special Recognition Award

5. Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse Highlights of Initiatives and Activities What’s Changing At NIDA? Future Directions

6. Highlights of NIDA Initiatives and Activities Highlights of NIDA Initiatives and Activities

7. “Neuroimaging Technology Development to Assess Brain and Behavior in Pediatric Populations” (RFA-DA-02-001) “Neuroimaging Technology Development to Assess Brain and Behavior in Pediatric Populations” (RFA-DA-02-001) 38 applications

8. National Prevention Research Initiative (NPRI) Basic Science In Prevention Research

9. New NIDA RFAs “NIDA National Prevention Research Initiative: Using Basic Science To Develop New Directions in Drug Abuse Prevention Research” (DA-02-010) “NIDA National Prevention Research Initiative: Using Basic Science To Develop New Directions in Drug Abuse Prevention Research” (DA-02-010) “NIDA National Prevention Research Initiative: Transdisciplinary Prevention Research Centers” (DA-02-005) “NIDA National Prevention Research Initiative: Transdisciplinary Prevention Research Centers” (DA-02-005) “Science Education NIDA National Prevention Research Initiative: Community Multi-Site Prevention Trials” (DA-02-004) “Science Education NIDA National Prevention Research Initiative: Community Multi-Site Prevention Trials” (DA-02-004) 31 applications 18 applications 5 applications

10. “National Criminal Justice Drug Abuse Treatment Research System” (RFA-DA-02-011) “National Criminal Justice Drug Abuse Treatment Research System” (RFA-DA-02-011) Issued: February 4, 2002 Application Receipt Date: May 13, 2002 Issued: February 4, 2002 Application Receipt Date: May 13, 2002 21 Applications

11. CTN “Expansion of the National Drug Abuse Treatment Clinical Trials Network” (RFA-DA-02-003) “Expansion of the National Drug Abuse Treatment Clinical Trials Network” (RFA-DA-02-003) 9 applications

12. “Modifying and Testing Efficacious Behavioral Therapies to Make Them More Community Friendly” (RFA-DA-02-006) “Modifying and Testing Efficacious Behavioral Therapies to Make Them More Community Friendly” (RFA-DA-02-006) 18 applications

13. “New Approaches to Prevent HIV/Other Infections in Drug Users” (RFA-DA-02-009) “New Approaches to Prevent HIV/Other Infections in Drug Users” (RFA-DA-02-009) 20 applications

14. “Hepatitis C Diagnosis, Treatment and Interaction with HIV/AIDS” (RFA-DA-02-008) “Hepatitis C Diagnosis, Treatment and Interaction with HIV/AIDS” (RFA-DA-02-008) 34 applications

15. Satellite Sessions for the XIV International AIDS Conference Satellite Sessions for the XIV International AIDS Conference Youth Drug Abuse and HIV Infection in Cultural Context Impact of Health Disparities on HIV Interventions in Drug- Using Populations Drug Abuse Treatment as HIV Prevention Effects of Drug Abuse and Sex Work on HIV Prevention Across National Borders HIV Risk Among Transgenders: The Social and Cultural Context of Substance Abuse Clarifying the Controversy About Whether Drug Abuse Influences AIDS Progression The Global Research Network on HIV Prevention in Drug- Using Populations Psychostimulant Abuse and HIV Risk Youth Drug Abuse and HIV Infection in Cultural Context Impact of Health Disparities on HIV Interventions in Drug- Using Populations Drug Abuse Treatment as HIV Prevention Effects of Drug Abuse and Sex Work on HIV Prevention Across National Borders HIV Risk Among Transgenders: The Social and Cultural Context of Substance Abuse Clarifying the Controversy About Whether Drug Abuse Influences AIDS Progression The Global Research Network on HIV Prevention in Drug- Using Populations Psychostimulant Abuse and HIV Risk

16. Released March 2002 Summary:  Prevention principles  Frequently asked questions  Epidemiology  NIDA’s major research programs Summary:  Prevention principles  Frequently asked questions  Epidemiology  NIDA’s major research programs

17. “Inhalant Abuse: Supporting Broad-Based Research Approaches” (RFA-DA-02-002) “Inhalant Abuse: Supporting Broad-Based Research Approaches” (RFA-DA-02-002) 30 applications

18. 10 th Annual National Inhalants and Poisons Awareness Week (NIPAW) 10 th Annual National Inhalants and Poisons Awareness Week (NIPAW) Press Conference Participants (Mar. 13, 2002): NIDA – Dr. David Shurtleff ONDCP – John Walters SAMHSA – Charles Curie CSAT – Westley Clark CSAP – Elaine Parry Partnership for a Drug Free America – Stephen Pasierb National Inhalant Prevention Coalition – Harvey Weiss NIDA – Dr. David Shurtleff ONDCP – John Walters SAMHSA – Charles Curie CSAT – Westley Clark CSAP – Elaine Parry Partnership for a Drug Free America – Stephen Pasierb National Inhalant Prevention Coalition – Harvey Weiss

20. New NIDA PAs “Science Education Drug Abuse Partnership Award” (PA-02-070) “Science Education Drug Abuse Partnership Award” (PA-02-070) “Neuroscience Research on Drug Addiction” (PA-02-085) “Neuroscience Research on Drug Addiction” (PA-02-085) “Chemistry, Pharmacology, and Toxicology of Smoked Drugs of Abuse” (PA-02-095) “Chemistry, Pharmacology, and Toxicology of Smoked Drugs of Abuse” (PA-02-095) “Imaging – Science Track Award For Research Transition (I/START)” (PAR-02-058) “Imaging – Science Track Award For Research Transition (I/START)” (PAR-02-058)

21. New PAs With Other NIH Components “Identifying Functional Links Between the Immune System and Brain Function Including Behavior” (PA-02-045) “Identifying Functional Links Between the Immune System and Brain Function Including Behavior” (PA-02-045) “Dissertation Research Grants for Underrepresented Minorities in the Ethical, Legal, and Social Implications (ELSI) of Genetic Research” (PA-02-048) “Dissertation Research Grants for Underrepresented Minorities in the Ethical, Legal, and Social Implications (ELSI) of Genetic Research” (PA-02-048) “Transitional Research Grants in Behavioral Science” (PA-02-061) “Transitional Research Grants in Behavioral Science” (PA-02-061) “Building Translational Research in Behavioral Science” (PAR-02-062) “Building Translational Research in Behavioral Science” (PAR-02-062) “Methodology and Measurement in the Behavioral and Social Sciences” (PAR-02-072) “Methodology and Measurement in the Behavioral and Social Sciences” (PAR-02-072) “Innovative Toxicology Models: SBIR/STTR” (PA-02-075) “Mentored Clinical Scientists Development Program Award” (K12 AWARD) (PAR-02-076) “Mentored Clinical Scientists Development Program Award” (K12 AWARD) (PAR-02-076)

22. New RFAs With Other NIH Components “Human Subjects Research Enhancements Program” (RFA-OD-02-003) “Human Subjects Research Enhancements Program” (RFA-OD-02-003) “Large-Scale Genotyping for the Haplotype Map of the Human Genome” (RFA-HG-02-005) “Large-Scale Genotyping for the Haplotype Map of the Human Genome” (RFA-HG-02-005) “Genetics in HIV/CNS Disease: Implications for Pathogenesis” (RFA-MH-02-012) “Genetics in HIV/CNS Disease: Implications for Pathogenesis” (RFA-MH-02-012)

23. NIH Extramural Loan Repayment Program Regarding Clinical Researchers NIH Extramural Loan Repayment Program Regarding Clinical Researchers Educational loan repayment programs (LRP) for Clinical, Pediatric, Contraceptive and Infertility, and Health Disparities Researchers from a Disadvantaged Background Educational loan repayment programs (LRP) for Clinical, Pediatric, Contraceptive and Infertility, and Health Disparities Researchers from a Disadvantaged Background

24. NIH Extramural Loan Repayment Program Regarding Clinical Researchers NIH Extramural Loan Repayment Program Regarding Clinical Researchers Purpose: Recruitment and retention of highly qualified health professionals as clinical investigators; Participants contractually agree to engage in clinical research as extramural grantees or awardees Purpose: Recruitment and retention of highly qualified health professionals as clinical investigators; Participants contractually agree to engage in clinical research as extramural grantees or awardees Provides for the repayment of up to $35,000 of awardees’ loans for each year of obligated service Provides for the repayment of up to $35,000 of awardees’ loans for each year of obligated service We’ll Be Talking More About This Topic This Afternoon… We’ll Be Talking More About This Topic This Afternoon… (NIDA-26; NIH- >600)

25. Highlights of Recent Meetings and Events Highlights of Recent Meetings and Events

27. EIC NIDA RWJ EIC NIDA RWJ 7 th Annual PRISM AWARDS 7 th Annual PRISM AWARDS May 9, 2002 Sponsored by:

28. Other Recent Meetings/Events “Strategies to Improve the Replicability, Sustainability, and Durability of HIV Prevention Interventions for Drug Users” “Strategies to Improve the Replicability, Sustainability, and Durability of HIV Prevention Interventions for Drug Users” Special Events Program (at the Society for Research on Adolescence) Special Events Program (at the Society for Research on Adolescence) “Cardiovascular Complications of HIV (& Substance Abuse)” HIV/AIDS, Viral Hepatitis and Addiction: Perspectives on Prevention and Treatment” (at ASAM Meeting) HIV/AIDS, Viral Hepatitis and Addiction: Perspectives on Prevention and Treatment” (at ASAM Meeting) “Lapse and Relapse: The Chronic, Recurring Nature of Drug Addiction” “Lapse and Relapse: The Chronic, Recurring Nature of Drug Addiction” “Mental Health Research Issues in HIV Infection and Aging”

29. Meetings Continued Enhancing Outcomes in Women’s Health

30. Coming Soon… Objective: -enhance practical use of research and rapid adaptation into drug abuse treatment Objective: -enhance practical use of research and rapid adaptation into drug abuse treatment

31. What Is Changing at NIDA? What Is Changing at NIDA? NORMAL Redefined NORMAL Redefined

32. Administration Congress Communities Changes in Expectations TRANSLATION & ACCOUNTABILITY

33. ONDCP SAMHSA Other NIH Institutes (particularly NIAAA, NIMH, NINDS) Other NIH Institutes (particularly NIAAA, NIMH, NINDS) Changes in Relationships

34. ONDCP Goal: to decrease drug abuse by 10% in 2 yrs. & 25% in 5 yrs. Goal: to decrease drug abuse by 10% in 2 yrs. & 25% in 5 yrs. CTN Medications Development Medications Development SAMHSA ATTC TEST SCIENCE MOVE SCIENCE INTO COMMUNITIES MOVE SCIENCE INTO COMMUNITIES NIH NIDA Define Common Science Issues NIAAA, NIMH, NINDS, etc. NIAAA, NIMH, NINDS, etc. DO SCIENCE

35. Future Directions

36. DRUGS BRAIN MECHANISMS BEHAVIOR ENVIRONMENT HISTORICAL ENVIRONMENTAL - previous history - expectation - learning - social interactions - stress - conditioned stimuli - genetics - circadian rhythms - disease states - gender PHYSIOLOGICAL We Need to Study the Effects of All of These Factors & Their Interactions in the Development, Progression & Treatment of Drug Abuse and Addiction We Need to Study the Effects of All of These Factors & Their Interactions in the Development, Progression & Treatment of Drug Abuse and Addiction

37. Neuroscience and Behavioral Research Initiatives Neuroproteomics Mapping Functional Circuits in the Brain Neural Plasticity and Long Term Changes Protein Trafficking Novel Drug Development Stress & Drug Abuse Drug Abuse Relapse Social Cognitive Neuroscience HIV/AIDSNeuroproteomics Mapping Functional Circuits in the Brain Neural Plasticity and Long Term Changes Protein Trafficking Novel Drug Development Stress & Drug Abuse Drug Abuse Relapse Social Cognitive Neuroscience HIV/AIDS

38. Epidemiology, Prevention and Services Research Develop frameworks to identify environmental risk factors & gene-environment interactions Examine biological predictors of drug use/abuse Examine proximal influences to drug abuse Determine drug abuse trends in underserved areas Develop frameworks to identify environmental risk factors & gene-environment interactions Examine biological predictors of drug use/abuse Examine proximal influences to drug abuse Determine drug abuse trends in underserved areas Epidemiology Prevention Test interventions targeted to specific high-risk populations Test delivery models & systems for identification & intervention with a wide range of problem clusters Test interventions targeted to specific high-risk populations Test delivery models & systems for identification & intervention with a wide range of problem clusters

39. Epidemiology, Prevention and Services Research (continued) Services Develop laboratories for blending research & practice in different settings Test treatment and recovery models which account for the chronic illness concept Test alternative models for treating criminal justice- involved drug abusers Determine which components of the treatment delivery systems are effective for adolescent drug abusers Develop laboratories for blending research & practice in different settings Test treatment and recovery models which account for the chronic illness concept Test alternative models for treating criminal justice- involved drug abusers Determine which components of the treatment delivery systems are effective for adolescent drug abusers

40. Treatment Research and Development Develop and screen new compounds active at novel sites Increase collaboration with other NIH ICs and pharmaceutical companies for medication development Immunotherapy Guidance and retraining models for counselors and therapists Develop and screen new compounds active at novel sites Increase collaboration with other NIH ICs and pharmaceutical companies for medication development Immunotherapy Guidance and retraining models for counselors and therapists

41. CTN Expansion Additional Nodes RFA 2002 Military nodes “Developing” Nodes? Additional Sites CTPs with special features As needed Additional Nodes RFA 2002 Military nodes “Developing” Nodes? Additional Sites CTPs with special features As needed

42. CAMCODA –Street youth Social and disease related –Counseling and Testing Does it work well? CAMCODA –Street youth Social and disease related –Counseling and Testing Does it work well? Trans NIDA –International Research Rural Drug driven epidemics –Hepatitis C Treatment issues –Disabled populations Physically disabled Mentally disabled Developmentally disabled Trans NIDA –International Research Rural Drug driven epidemics –Hepatitis C Treatment issues –Disabled populations Physically disabled Mentally disabled Developmentally disabled CAMCODA TOPICS

43. Future Directions Future Directions We Want FEEDBACK! We Want FEEDBACK!

44. We Want Feedback On Philosophy Proposed Initiatives What we should be doing What we should not be doing